Skip to main content
Susan C. Pitt, MD, MPHS
Back to Writing
OverdiagnosisNovember 2025

The Language of Cancer: Why Words Matter in Diagnosis

When we call something "cancer," patients hear a death sentence. For low-risk thyroid disease, that word may do more harm than the disease itself.

Dr. Susan C. Pitt

Susan C. Pitt, MD, MPHS

University of Michigan

Words shape reality. In medicine, few words carry more weight than "cancer." The moment a physician says that word, the patient's world shifts. Plans are rearranged. Futures are reconsidered. Fear becomes the dominant emotion. But what happens when the condition labeled "cancer" behaves nothing like the disease that word conjures in a patient's mind?

The Weight of a Word

Research consistently shows that patients diagnosed with low-risk papillary thyroid cancer experience levels of anxiety comparable to those diagnosed with aggressive, life-threatening cancers. The biological reality — that their condition poses minimal risk — is overshadowed by the psychological impact of the label. They hear "cancer" and think of chemotherapy, suffering, and mortality, even when none of those apply to their situation.

This disconnect between label and reality has measurable consequences. Patients with low-risk thyroid cancer who hear the word "cancer" are significantly more likely to choose aggressive treatment — total thyroidectomy rather than lobectomy, surgery rather than surveillance — even when the evidence suggests that less invasive approaches yield equivalent outcomes. The word itself becomes a driver of overtreatment.

Reclassification as a Solution

In 2016, a landmark reclassification renamed a common thyroid lesion from "encapsulated follicular variant of papillary thyroid carcinoma" to "noninvasive follicular thyroid neoplasm with papilloid nuclear features" — or NIFTP. The change removed the word "carcinoma" from the diagnosis. Studies have shown that this reclassification reduced patient anxiety and decreased the rate of unnecessary completion thyroidectomies.

The NIFTP example demonstrates that changing language can change outcomes. It raises a provocative question: should we consider similar reclassifications for other low-risk conditions currently labeled as cancer? The idea is controversial, but the evidence supporting it grows stronger each year.

The language of medicine is not neutral. When we label a condition, we shape how patients experience it, how clinicians treat it, and how society understands it. Getting the language right is not a matter of semantics — it is a matter of patient welfare.
Share

Written By

Dr. Susan C. Pitt

Susan C. Pitt, MD, MPHS

Associate Professor of Surgery & Vice Chair for Faculty Development

Dr. Pitt is an endocrine surgeon, NIH-funded researcher, and writer at the University of Michigan. Her work focuses on reducing overtreatment of thyroid cancer, empowering patients through shared decision-making, and championing equity in surgical care.